4.3 Article

Clinical and Quality of Life Outcomes Following Temperature-Controlled Radiofrequency Neurolysis of the Posterior Nasal Nerve (RhinAer) for Treatment of Chronic Rhinitis

期刊

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
卷 36, 期 6, 页码 747-754

出版社

SAGE PUBLICATIONS INC
DOI: 10.1177/19458924221109987

关键词

radiofrequency; temperature-controlled; neurolysis; posterior nasal nerve; rTNSS; chronic rhinitis; quality of life; MiniRQLQ

资金

  1. Aerin Medical

向作者/读者索取更多资源

Temperature-controlled radiofrequency neurolysis of the posterior nasal nerve (PNN) is a safe and effective treatment option for patients with chronic rhinitis, leading to significant improvement in symptoms and quality of life.
Background Temperature-controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve (PNN; RhinAer) is a minimally invasive treatment option for patients with chronic rhinitis. Objective To determine clinical outcomes and quality of life (QoL) following TCRF neurolysis of the PNN. Methods A prospective single-arm study of 129 patients with chronic rhinitis at 16 medical centers in the United States and Germany. Results The mean 24-h reflective total nasal symptom score (rTNSS) improved from 7.8 (95% CI, 7.5-8.1) at baseline to 3.6 (95% CI, 3.2-4.0) at 3 months and continued to improve to 2.9 (95% CI, 2.5-3.3) at 6 months (p < .001 comparing follow-up to baseline and p = .002 comparing 3 and 6 months). This represents 53.8% improvement over baseline at 3 months and 62.8% improvement at 6 months. Rhinorrhea, congestion, sneezing, and itching subscores and postnasal drip and cough scores were all significantly improved over baseline at both timepoints. At 3 months, 76.2% (95% CI, 68.1%-82.8%) of patients achieved a minimal clinically important difference of >= 30% improvement in rTNSS over baseline and the percentage was higher at 6 months (83.5% [95% CI, 75.8%-89.0%]). At 3 months, 80.3% (95% CI, 72.6%-86.3%) reported a minimal clinically important difference of >= 0.4-point improvement in the mini rhinoconjunctivitis quality of life questionnaire score, and the percentage was higher at 6 months; 87.7% (95% CI, 80.7%-92.4%). There were no serious adverse events with a relationship to the device/procedure reported through 6 months. Conclusion In this large, multicenter study, TCRF neurolysis of the PNN was safe and resulted in a significant reduction in rhinitis symptom burden at 3 months that was sustained/improved through 6 months. The majority of patients reported a clinically relevant improvement in QoL at 3 and 6 months postprocedure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据